SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Agouron Pharmaceuticals (AGPH)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: sam who wrote (1999)10/2/1997 11:05:00 AM
From: Henry Niman   of 6136
 
LGND currently has Panretin to topically treat KS. The Phase III data was very strong and the international trial was halted. Results of the US trial are due out soon and since the design was similar (but didn't have a provision for halting the trial based on interim data, it went to completion), similar results are expected. The AIDS consortium is testing the oral version of the drug to test for improvement of immunological markers. As far as I know the drug does not attack HIV directly. Panretin is 9-cis retinoic acid which is a non-polypeptide hormone (first one discovered in over 25 years) and its mode of action is really directed at the cells, not the virus.

Here are the Objectives of that study:
I. Evaluate the safety and tolerability of oral 9-cis-retinoic acid (9-CRA)
in patients with AIDS-related Kaposi's sarcoma.

II. Assess the antitumor effects of oral 9-CRA in these patients.

III. Evaluate the effect of 9-CRA on human immunodeficiency virus (HIV)
replication and immune parameters using HIV ribonucleic acid polymerase chain
reaction and lymphocyte subset cell counts.

IV. Correlate changes in cytokine expression with tumor response.

LGND has an extensive anti-progestin program with AHP focusing on women's health. I think that applications toward HIV are relatively new (they are to me) and LGND has not mentioned a specific anti-HIV program using anti-progestins (but they have many compounds).

LGND's screening is disease-independent. They use a panel of hormone receptors to identify compunds with angonist or antagonist properties.
An application to a viral component is very new and I doubt that mutation rates are known (if they are, I don't know them).
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News